minocycline and Rheumatic-Diseases

Over the past several decades, rheumatology has directed its focus to understanding and countering the immune dysregulation underlying autoimmune diseases with rheumatologic manifestations. Older therapies, effective though poorly understood, are being scrutinized anew and are yielding the immune-modulating mechanisms behind their efficacy. New therapies, the "biologics," are drugs tailored to address specific immune defects and imbalances. This article discusses the current standard and biologic immunotherapies of the rheumatic diseases, correlating our current understanding of their mechanisms with dysfunctions believed to be present in the major autoimmune syndromes, especially rheumatoid arthritis and systemic lupus erythematosus.

Topics: Abatacept; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Azathioprine; Certolizumab Pegol; Colchicine; Cyclophosphamide; Cyclosporine; Etanercept; Glucocorticoids; Humans; Hydroxychloroquine; Immunoconjugates; Immunoglobulin Fab Fragments; Immunoglobulin G; Infliximab; Interleukin 1 Receptor Antagonist Protein; Isoxazoles; Leflunomide; Methotrexate; Minocycline; Mycophenolic Acid; Polyethylene Glycols; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Rheumatic Diseases; Rituximab; Sulfasalazine; Tumor Necrosis Factor Inhibitors

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cartilage; Cartilage, Articular; Horses; Humans; Lung Diseases; Minocycline; Rheumatic Diseases; Steroids; Surface Properties; Surface-Active Agents; Synovial Fluid